QLT settles Massachusetts Eye and Ear Infirmary patent lawsuit

QLT Inc. announced that the parties have settled the litigation brought in 2001 by Massachusetts Eye and Ear Infirmary ("MEEI") against QLT and Novartis Ophthalmics, Inc., case # 01-10747, in the United States District Court for the District of Massachusetts (the "District Court").

Under the terms of the settlement agreement, MEEI will dismiss with prejudice its claims for infringement of U.S. Patent # 6,225,303 (the " '303 Patent") against QLT and Novartis Ophthalmics, Inc. and QLT and Novartis will dismiss their counterclaims against MEEI and named MEEI researchers. QLT, MEEI and Massachusetts General Hospital ("MGH") have agreed to resolve by arbitration counterclaims raised by QLT and MGH that researchers from QLT and MGH should have been named as inventors on the '303 Patent. The outcome of the arbitration will have no effect on the settlement.

The settlement of the '303 Patent lawsuit does not resolve the separate '349 patent lawsuit brought in 2000 by MEEI against QLT in the District Court, # 00-10783. The parties have filed post-trial motions in connection with the '349 patent lawsuit. The timing of a final decision in the '349 patent lawsuit is uncertain.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Danish studies find increased risk of optic nerve damage with diabetes medicine